Nordic VC Firms Expand to Listed Biotechs in Hunt for Bargains
- HealthCap, Sound Bioventures shift focus from private markets
- Bear market made biotech valuations attractive, investors say
This article is for subscribers only.
Two Nordic early-stage biotech investors are warming to the idea of buying into listed companies that have become too cheap to ignore.
Venture capital firms HealthCap and Sound Bioventures are shifting from a playbook mostly based on finding targets in the private sphere after the bear market made valuations of some publicly traded firms very appealing.